BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 24857402)

  • 1. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures.
    Brazier J; Connell J; Papaioannou D; Mukuria C; Mulhern B; Peasgood T; Jones ML; Paisley S; O'Cathain A; Barkham M; Knapp M; Byford S; Gilbody S; Parry G
    Health Technol Assess; 2014 May; 18(34):vii-viii, xiii-xxv, 1-188. PubMed ID: 24857402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.
    Longworth L; Yang Y; Young T; Mulhern B; Hernández Alava M; Mukuria C; Rowen D; Tosh J; Tsuchiya A; Evans P; Devianee Keetharuth A; Brazier J
    Health Technol Assess; 2014 Feb; 18(9):1-224. PubMed ID: 24524660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).
    Brazier JE; Rowen D; Mavranezouli I; Tsuchiya A; Young T; Yang Y; Barkham M; Ibbotson R
    Health Technol Assess; 2012 Jul; 16(32):1-114. PubMed ID: 22832015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D.
    Mulhern B; Mukuria C; Barkham M; Knapp M; Byford S; Soeteman D; Brazier J
    Br J Psychiatry; 2014 Sep; 205(3):236-43. PubMed ID: 24855127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the psychometric properties of generic utility measures in multiple sclerosis.
    Kuspinar A; Mayo NE
    Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of health-related quality of life in individuals with depressive symptoms: validity and responsiveness of the EQ-5D-3L and the SF-6D.
    Stolz M; Albus C; Beutel ME; Deter HC; Fritzsche K; Herrmann-Lingen C; Michal M; Petrowski K; Ronel J; Schultz JH; Söllner W; Weber C; de Zwaan M; Krauth C
    Eur J Health Econ; 2023 Nov; 24(8):1297-1307. PubMed ID: 36385438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring quality of life in mental health: are we asking the right questions?
    Connell J; O'Cathain A; Brazier J
    Soc Sci Med; 2014 Nov; 120():12-20. PubMed ID: 25194472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis.
    Mukuria C; Rowen D; Acaster S; McGarry LJ; Lou Y; Sosnay PR; Quittner AL
    J Patient Rep Outcomes; 2024 Feb; 8(1):24. PubMed ID: 38416239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
    Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
    Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
    Wong CKH; Lang BHH; Yu HMS; Lam CLK
    Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review.
    Papaioannou D; Brazier J; Parry G
    Value Health; 2011; 14(6):907-20. PubMed ID: 21914513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.
    Parker M; Haycox A; Graves J
    Pharmacoeconomics; 2011 Aug; 29(8):719-30. PubMed ID: 21635017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EQ-5D in skin conditions: an assessment of validity and responsiveness.
    Yang Y; Brazier J; Longworth L
    Eur J Health Econ; 2015 Dec; 16(9):927-39. PubMed ID: 25358263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.
    Aggarwal R; Wilke CT; Pickard AS; Vats V; Mikolaitis R; Fogg L; Block JA; Jolly M
    J Rheumatol; 2009 Jun; 36(6):1209-16. PubMed ID: 19369452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients.
    Wu J; Han Y; Zhao FL; Zhou J; Chen Z; Sun H
    Health Qual Life Outcomes; 2014 Oct; 12():156. PubMed ID: 25343944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
    Cheung PWH; Wong CKH; Cheung JPY
    Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric properties of Patient Reported Outcome Measures (PROMs) in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS).
    Shah HA; Dritsaki M; Pink J; Petrou S
    Health Qual Life Outcomes; 2016 Jan; 14():15. PubMed ID: 26818098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness and minimally important difference of SF-6D and EQ-5D utility scores for the treatment of pelvic organ prolapse.
    Harvie HS; Honeycutt AA; Neuwahl SJ; Barber MD; Richter HE; Visco AG; Sung VW; Shepherd JP; Rogers RG; Jakus-Waldman S; Mazloomdoost D;
    Am J Obstet Gynecol; 2019 Mar; 220(3):265.e1-265.e11. PubMed ID: 30471259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.